Biotech Values

[vinmantoo]

That deal worked out for me as an investor although it wasn’t a major score for me. If I recall, a worry about Magrolimab was binding to RBCs could cause issues. TRILs Abs were supposed to not have that problem.

I wonder if GILD might be a suitor for VKTX given their interest in the anti-obesity drug area.